Patents Assigned to Tokyo Metropolitan Organization for Medical Research
-
Patent number: 9134313Abstract: A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.Type: GrantFiled: June 9, 2009Date of Patent: September 15, 2015Assignees: Tokyo Metropolitan Organization For Medical Research, CRC Inc., Tokyo Metropolitan Government, Trans Genic Inc.Inventors: Masao Kawakita, Kyoko Hiramatsu, Keiichi Takahashi, Naotaka Hamasaki, Koji Yamaguchi, Tsunehisa Kaku, Koichiro Muta, Munechika Enjoji, Seiji Naito, Jun Hayashi, Shoshu Mitsuyama, Hiroyuki Yamashita, Toru Inoue, Masato Kato
-
Patent number: 8604179Abstract: This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5? to 3? direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.Type: GrantFiled: April 24, 2009Date of Patent: December 10, 2013Assignees: Toray Industries, Inc., Japan As Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Organization for Medical ResearchInventors: Daisuke Akazawa, Takaji Wakita
-
Publication number: 20130064805Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: November 2, 2012Publication date: March 14, 2013Applicants: ALTIF LABORATORIES, TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCHInventors: TOKYO METROPOLITAN ORGANIZATION FOR, ALTIF LABORATORIES
-
Patent number: 8323640Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: GrantFiled: March 21, 2011Date of Patent: December 4, 2012Assignees: Tokyo Metropolitan Organization For Medical Research, Altif LaboratoriesInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20110275139Abstract: Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above.Type: ApplicationFiled: March 6, 2009Publication date: November 10, 2011Applicants: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCHInventors: Michinori Kohara, Fukashi Murai
-
Patent number: 8022197Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.Type: GrantFiled: September 16, 2004Date of Patent: September 20, 2011Assignees: Tokyo Metropolitan Organization for Medical Research, Toray Industries Inc.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
-
Publication number: 20110189690Abstract: In order to improve the detection sensitivity of MUSTag, the present invention provides an antibody complex including a nucleic acid chain as a label, an antibody to specifically recognize the antigen and an adaptor moiety linking the nucleic acid chain and the antibody, wherein the adaptor moiety includes an immunoglobulin binding domain of Protein G, Protein A or Protein L for binding with the antibody, and the adaptor moiety and the antibody are chemically cross-linked to form a cross-linked antibody complex.Type: ApplicationFiled: June 30, 2009Publication date: August 4, 2011Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, SYNTHERA TECHNOLOGIES CO., LTD.Inventors: Futoshi Shibasaki, Yoshihito Morizane
-
Publication number: 20110171198Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: March 21, 2011Publication date: July 14, 2011Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIESInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20110137196Abstract: The system of the present invention includes (a) means for displaying image information including a target image and a cursor image for tracking the target image; (b) means used when the subject moves the cursor image; (c) means for detecting the state of tracking the target image by the cursor image; (d) means for detecting the muscle active state of the subject using the means (b); (e) means for analyzing the tracking state detected by the means (c) and the muscle active state detected by the means (d); and (f) means for evaluating the motor function of the subject by using results of analysis obtained by the means (e) as indexes.Type: ApplicationFiled: February 26, 2008Publication date: June 9, 2011Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, TOKYO METROPOLITAN GOVERNMENTInventors: Shinji Kakei, Jongho Lee, Yasuhiro Kagamihara
-
Patent number: 7935676Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.Type: GrantFiled: November 25, 2003Date of Patent: May 3, 2011Assignees: Toray Industries Inc., Tokyo Metropolitan Organization for Medical Research, Ralf BartenschlagerInventors: Takaji Wakita, Takanobu Kato, Tomoko Date
-
Patent number: 7935336Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: GrantFiled: November 17, 2006Date of Patent: May 3, 2011Assignees: Tokyo Metropolitan Organization for Medical Research, ALTIF LaboratoriesInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20110092688Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.Type: ApplicationFiled: December 1, 2010Publication date: April 21, 2011Applicants: TORAY INDUSTRIES, INC., Tokyo Metropolitan Organization for Medical ResearchInventors: Takaji WAKITA, Takanobu Kato, Tomoko Date
-
Patent number: 7858313Abstract: A method of evaluating drug sensitivity or disease vulnerability, includes linking a gene polymorphism in a GIRK channel gene or a haplotype comprising the gene polymorphism to individual drug sensitivity or individual disease vulnerability.Type: GrantFiled: August 30, 2007Date of Patent: December 28, 2010Assignee: Tokyo Metropolitan Organization for Medical ResearchInventors: Kazutaka Ikeda, Masakazu Hayashida, Daisuke Nishizawa, Ichiro Sora
-
Publication number: 20100240552Abstract: The present invention provides a method for predicting the difference in drug sensitivity among individuals by using a genetic polymorphism of the POMC gene. Specifically, the present invention provides a method for evaluating drug sensitivity, comprising associating a genetic polymorphism of POMC gene with an individual drug sensitivity.Type: ApplicationFiled: April 25, 2008Publication date: September 23, 2010Applicant: Tokyo Metropolitan Organization for Medical ResearchInventors: Kazutaka Ikeda, Shinya Kasai, Masakazu Hayashida, Susumu Higuchi
-
Patent number: 7790448Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.Type: GrantFiled: September 12, 2007Date of Patent: September 7, 2010Assignees: Tokyo Metropolitan Organization for Medical Research, Toray Industries, Inc.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
-
Publication number: 20100166728Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: November 17, 2006Publication date: July 1, 2010Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIESInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20100047896Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.Type: ApplicationFiled: August 21, 2009Publication date: February 25, 2010Applicants: Tokyo Metropolitan Organization for Medical Research, TORAY INDUSTRIES, INC.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
-
Publication number: 20100047826Abstract: The present invention has the object of providing a cell into which a protein, which can serve as a polymerization nucleus of a protein polymer, or polymer thereof is introduced, and a method for producing the cell. The invention relates to a cell into which a protein, which can serve as a polymerization nucleus of a protein polymer, or a polymer thereof is introduced, a method for producing the cell, and a method of screening for a compound inhibiting an intracellular accumulation of a protein containing fibril structures, wherein the method comprises bringing a candidate substance into contact with the cell.Type: ApplicationFiled: December 6, 2006Publication date: February 25, 2010Applicant: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCHInventors: Takashi Nonaka, Sayuri Watanabe, Masami Masuda, Masato Hasegawa
-
Patent number: 7659103Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.Type: GrantFiled: February 21, 2005Date of Patent: February 9, 2010Assignees: Tokyo Metropolitan Organization For Medical Research, Toray Industries, Inc.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
-
Publication number: 20090298098Abstract: A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.Type: ApplicationFiled: June 9, 2009Publication date: December 3, 2009Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, CRC Inc., Tokyo Metropolitan Government, Trans Genic Inc.Inventors: Masao KAWAKITA, Kyoko HIRAMATSU, Keiichi TAKAHASHI, Naotaka HAMASAKI, Koji YAMAGUCHI, Tsunehisa KAKU, Koichiro MUTA, Munechika ENJOJI, Seiji NAITO, Jun HAYASHI, Shoshu MITSUYAMA, Hiroyuki YAMASHITA, Toru INOUE, Masato KATO